Daiichi Sankyo Company Beheer

Beheer criteriumcontroles 3/4

De CEO Daiichi Sankyo Company is Hiroyuki Okuzawa, benoemd in Apr2023, heeft een ambtstermijn van 3.08 jaar. De totale jaarlijkse vergoeding van { bedraagt ¥ 252.00M, bestaande uit 33.3% salaris en 66.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.003% van de aandelen van het bedrijf, ter waarde $ 863.91K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.7 jaar en 2.4 jaar.

Belangrijke informatie

Hiroyuki Okuzawa

Algemeen directeur

JP¥252.0m

Totale compensatie

Percentage CEO-salaris	33.33%
Dienstverband CEO	3.1yrs
Eigendom CEO	0.003%
Management gemiddelde ambtstermijn	2.7yrs
Gemiddelde ambtstermijn bestuur	2.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Hiroyuki Okuzawa's beloning veranderd ten opzichte van Daiichi Sankyo Company's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Mar 31 2026	n/a	n/a	JP¥260b
Dec 31 2025	n/a	n/a	JP¥305b
Sep 30 2025	n/a	n/a	JP¥280b
Jun 30 2025	n/a	n/a	JP¥296b
Mar 31 2025	JP¥252m	JP¥84m	JP¥296b
Dec 31 2024	n/a	n/a	JP¥246b
Sep 30 2024	n/a	n/a	JP¥250b
Jun 30 2024	n/a	n/a	JP¥229b
Mar 31 2024	JP¥252m	JP¥84m	JP¥201b
Dec 31 2023	n/a	n/a	JP¥186b
Sep 30 2023	n/a	n/a	JP¥148b
Jun 30 2023	n/a	n/a	JP¥147b
Mar 31 2023	JP¥151m	JP¥51m	JP¥109b

Compensatie versus markt: De totale vergoeding ($USD 1.58M ) Hiroyuki } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 14.74M ).

Compensatie versus inkomsten: De vergoeding van Hiroyuki is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Hiroyuki Okuzawa (63 yo)

3.1yrs

Tenure

JP¥252,000,000

Compensatie

Mr. Hiroyuki Okuzawa is Chief Executive Officer of Daiichi Sankyo Company, Limited from April 1, 2025 and was its Chief Operating Officer until April 1, 2025. He is President of Daiichi Sankyo Company, Lim...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sunao Manabe	Executive Chairperson	11.9yrs	JP¥342.00m	0.0092% $ 2.8m
Hiroyuki Okuzawa	President	3.1yrs	JP¥252.00m	0.0028% $ 863.9k
Tomohiro Kodama	Senior Executive Officer	less than a year	geen gegevens	geen gegevens
Tetsuya Ohira	Corporate Officer	less than a year	geen gegevens	geen gegevens
Naoto Tsukaguchi	Senior Executive Officer	no data	geen gegevens	geen gegevens
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	2.3yrs	geen gegevens	geen gegevens
Takashi Matsumoto	Sr. Exec Ofcr	3.1yrs	geen gegevens	0.0025% $ 762.1k
Joji Nakayama	Senior Adviser	5.9yrs	JP¥185.00m	geen gegevens
Joseph Kenneth Keller	Head of Oncology Business Unit & Global Oncology Business and Director	no data	geen gegevens	geen gegevens
Stuart Mackey	Global Head of Business Development	no data	geen gegevens	geen gegevens
Thierry Gruson	Head of Global Oncology Marketing	no data	geen gegevens	geen gegevens
Kento Wada	Global Head of Clinical Safety & Pharmacovigilance Unit	no data	geen gegevens	geen gegevens

2.7yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DSKY.F wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sunao Manabe	Executive Chairperson	11.9yrs	JP¥342.00m	0.0092% $ 2.8m
Hiroyuki Okuzawa	President	4.9yrs	JP¥252.00m	0.0028% $ 863.9k
Takashi Matsumoto	Sr. Exec Ofcr	1.9yrs	geen gegevens	0.0025% $ 762.1k
Joseph Kenneth Keller	Head of Oncology Business Unit & Global Oncology Business and Director	less than a year	geen gegevens	geen gegevens
Shizuko Ueno	Senior Executive Officer	less than a year	geen gegevens	geen gegevens
Reiko Kinoshita	Independent Outside Director	less than a year	geen gegevens	geen gegevens
Akihiro Hiroshi Watanabe	Independent Outside Director	less than a year	geen gegevens	geen gegevens
Yo Honma	Independent Outside Director	1.9yrs	geen gegevens	0.000050% $ 15.4k
Takaaki Nishii	Independent Outside Chairperson	2.9yrs	geen gegevens	0.00016% $ 49.4k
Miyuki Arai	Chairperson Member of Audit & Supervisory Board	2.9yrs	geen gegevens	0.0011% $ 354.8k
Yukiko Imazu	Outside Audit & Supervisory Board Member	7.9yrs	geen gegevens	geen gegevens
Yasuhiro Komatsu	Independent Outside Director	3.9yrs	geen gegevens	geen gegevens

2.4yrs

Gemiddelde duur

62.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DSKY.F wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.4 jaar), wat duidt op een nieuw bestuur.

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/31 20:52
Aandelenkoers aan het einde van de dag	2026/05/28 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2026/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Daiichi Sankyo Company, Limited wordt gevolgd door 27 analisten. 15 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Atsushi Seki	Barclays
Miki Sogi	Bernstein
Koichi Mamegano	BofA Global Research

Daiichi Sankyo Company Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 22, 2026

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Recent updates

Daiichi Sankyo Presents New Clinical Research And Product Pipeline Updates Across Oncology Portfolio At ASCO

Daiichi Sankyo and Astrazeneca Announce Approval of Datroway as First Trop2 Directed Antibody Drug Conjugate for First-Line Treatment of Metastatic Triple Negative Breast Cancer in the U.S

Astrazeneca and Daiichi Sankyo Receive Us Approval for Enhertu for Two New Indications in Her2-Positive Early Breast Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 22, 2026

Suntory Holdings Limited signed a letter of intent to acquire Daiichi Sankyo Healthcare Co., Ltd. from Daiichi Sankyo Company, Limited (TSE:4568) for approximately ¥250 billion.

Daiichi Sankyo Company, Limited to Report Q4, 2026 Results on Apr 27, 2026

Daiichi Sankyo And AstraZeneca Announce Acceptance And Priority Review Of Supplemental Biologics License Application For ENHERTU For HER2 Positive Breast Cancer

Daiichi Sankyo Company, Limited Announces Board Retirements, Effective March 31, 2026

Daiichi Sankyo Company, Limited Announces Executive Changes, Effective April 1, 2026

European Medicines Agency Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer

Daiichi Sankyo Announces First Patient Has Been Dosed in A First-In-Human Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Receive Priority Review For DATROWAY For Treatment Of Unresectable Or Metastatic Triple Negative Breast Cancer In The U.S

National Medical Products Administration Approves Enhertu in China as the First and Only Her2 Directed Dc for the Second-Line Treatment of Patients with Her2 Positive Metastatic Gastric Cancer

Daiichi Sankyo Appoints Veronika Rozehnal, Ph.D., as Head of Translational Research Center Europe

European Medicines Agency Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer

TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

Enhertu® Granted Breakthrough Therapy Designation in the U.S. as Post-Neoadjuvant Therapy for Patients with Her2 Positive Early Breast Cancer

Daiichi Sankyo and AstraZeneca's DATROWAY® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy

Astrazeneca and Daiichi Sankyo's ENHERTU®? (Fam-Trastuzumab Deruxtecan-nxki) Approves in the US as First New Treatment in A decade for the 1st-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Destiny-Ovarian01 Phase 3 Trial of Enhertu Initiated as First-Line Maintenance Therapy in Patients with Her2 Expressing Advanced Ovarian Cancer

Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute Between Daiichi Sankyo and Seagen

Daiichi Sankyo Company, Limited to Report Q3, 2026 Results on Jan 30, 2026

Daiichi Sankyo Announces Dosed in First-In-Human Phase 1 Trial Evaluating Ds3610 in Patients with Advanced Solid Tumors

DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited Announces DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial

Daiichi Sankyo And AstraZeneca Present Initial Results For DATROWAY Plus Rilvegostomig Combination Therapy in Urothelial Cancer

Daiichi Sankyo Continues to Transform Standards of Care for Patients with Three Landmark Breast Cancer Trials

AstraZeneca and Daiichi Sankyo Announces Positive High-Level Results from the TROPION-Breast02 Phase III Trial

Daiichi Sankyo and Astrazeneca's Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk Her2 Positive Early-Stage Breast Cancer Prior to Surgery

Daiichi Sankyo and AstraZeneca's Supplemental Biologics License Application for Enhertu®? in Combination with Pertuzumab Deruxtecan-nxki

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Daiichi Sankyo Company, Limited to Report Q2, 2026 Results on Oct 31, 2025

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

Daiichi Sankyo Presents New Data in Small Cell Lung Cancer and Updates Across Adc Portfolio Highlighting Progress in Creating New Standards of Care for Patients with Lung Cancer At Wclc

Enhertu Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with Her2 Positive Metastatic Breast Cancer

Turalio Final Long-Term Data Showed Sustained Clinical Benefit in Patients with Tenosynovial Giant Cell Tumor from Open-Label Extension of Enliven Phase 3 Trial

Datroway Approves in Us for EGFRm Lung Cancer

IDeate-Prostate01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Pretreated Metastatic Castration-Resistant Prostate Cancer

Daiichi Sankyo Company, Limited to Report Q1, 2026 Results on Jul 31, 2025

DATROWAY Continues to Show Promising Tumor Responses as Part of Combination Regimens in Patients with Early and Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo and Merck Announces Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntary Withdraw

IHH Healthcare Berhad Provides Update on Material Litigation by Northern TK Venture Pte Ltd Against Daiichi Sankyo Company, Limited

Daiichi Sankyo, Inc. Announces Positive Topline Results from the Destiny-Breast11 Phase 3 Trial

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 23, 2025

Enhertu Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer

Daiichi Sankyo and AstraZeneca Announce European Union Approves DATROWAY®? for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Daiichi Sankyo and AstraZeneca's ENHERTU Approves in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited to Report Fiscal Year 2025 Results on Apr 25, 2025

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 17,000,000 shares, representing 0.91% for ¥50,000 million.

Daiichi Sankyo and AstraZeneca's Enhertu Recommends for Approval in the EU by CHMP for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Following at Least One Endocrine Therapy

Daiichi Sankyo Company, Limited Provides Updated on Claim Before the Tokyo District Court in Japan by Northern TK Venture Pte Ltd

Daiichi Sankyo Company, Limited Announces Chief Executive Officer Changes, Effective April 1, 2025

Daiichi Sankyo's Datopotamab Deruxtecan is Recommended for Approval in the EU by CHMP for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

AstraZeneca PLC and Daiichi Sankyo’ ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Approves in the US for the Treatment of Adult Patients with Unresectable or Metastatic Hormone Receptor (HR)-Positive, HER2-Low (IHC 1+ or IHC 2+/ISH-) or Her2-Ultralow (IHC 0 with Membrane Staining) Breast Cancer

Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

AstraZeneca and Daiichi Sankyo Voluntarily Withdrawn the Marketing Authorisation Application in the EU for datopotamab deruxtecan (Dato-DXd)

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

Quantum-Wild Phase 3 Trial of VANFLYTA Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML

Daiichi Sankyo Company, Limited to Report Q3, 2025 Results on Jan 31, 2025

Daiichi Sankyo to Showcase TURALIO Research in Patients with Tenosynovial Giant Cell Tumor at CTOS

Daiichi Sankyo and AstraZeneca Submits New Biologics License Application for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Daiichi Sankyo and AstraZeneca Announce Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer

Astrazeneca and Daiichi Sankyo's Supplemental Biologics License Application for ENHERTU (Fam-Trastuzumab Deruxtecan-nxki) Accepted and Granted Priority Review in the US

Enhertu Grants Daiichi Sankyo and Astrazeneca Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received At Least One Line of Endocrine Therapy

Datopotamab Deruxtecan Significantly Extended Progression-Free Survival Versus Chemotherapy in Patients with Hr Positive, Her2 Low or Negative Breast Cancer in Patients with Hr Positive, Her2 Low or Negative Breast Cancer

Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases